透景生命 reported revenue of ¥0.19B for the period ended 2026-06-30, +17.8% year on year. Net income was ¥0.01B, a 5.8% net margin on a 67.0% gross margin. The largest revenue line is 试剂收入 at 90% of the total. Free cash flow for the period was ¥0.09B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.19B | +17.8% |
| Gross profit | ¥0.13B | — |
| Operating income | ¥0.02B | — |
| Net income | ¥0.01B | +3136.5% |
| Gross margin | 67.0% | Net margin 5.8% |
| Revenue Q/Q | +26.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 试剂收入 | ¥0.17B | 89.7% |
| 仪器收入 | ¥0.02B | 9.5% |
| 服务收入 | ¥0.00B | 0.8% |
| 其他 | ¥0.00B | 0.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.06B | 33.0% |
| R&D | ¥0.03B | 16.1% |
| SG&A | ¥0.08B | 44.3% |
| Tax & other | ¥0.01B | 3.2% |
| Item | Amount |
|---|---|
| Total assets | ¥2.01B |
| Total liabilities | ¥0.54B |
| Shareholders' equity | ¥1.48B |
| Equity / assets | 73.3% |
| Operating cash flow | ¥0.10B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.09B |
| Cash conversion (OCF / net income) | 962% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
万通智控 ・ 南京聚隆 ・ 正元智慧 ・ 超频三 ・ 星云股份 ・ 杭州园林 ・ 太龙股份 ・ 金陵体育 ・ 雷迪克 ・ 正海生物 ・ 世纪天鸿 ・ 晶瑞电材
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies